MapLight Therapeutics Initiates Phase 2 Trial for ML-007C-MA in Schizophrenia

MapLight Therapeutics has begun a Phase 2 clinical trial (ZEPHYR) to assess the efficacy, safety, and tolerability of ML-007C-MA, a novel M1/M4 muscar...
Home/KnloSights/Clinical Trial Updates/MapLight Therapeutics Initiates Phase 2 Trial for ML-007C-MA in Schizophrenia